Conditions: Liver Diseases
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 38
Healthy volunteers: no

Brief summary:
This is an open label, multi-centre, dose ranging study to assess efficacy, safety and pharmacokinetics of eltrombopag in thrombocytopenic subjects with chronic liver disease.

Detailed description:

Arms:
arm 1: eltrombopag 12.5 mg/day arm 2: eltrombopag 25 mg/day arm 3: eltrombopag 37.5 mg/day

Interventions: intervention 1: eltrombopag 12.5 milligrams (mg) tablet intervention 2: eltrombopag 25 mg tablet
Intervention descriptions: intervention 1: eltrombopag 12.5 mg tablet once a day intervention 2: eltrombopag 25 mg tablet once a day

Protocol document: